Career Enhancement Program

职业提升计划

• 批准号: 10494113
• 负责人: KEVIN M. SHANNON
• 金额: $ 9.39万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-01 至 2026-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10494113
• 关键词: Acceleration; Address; Area; Award; Basic Science; California; Cancer Biology; Cancer Center; Child; Clinical; Clinical Investigator; Clinical Sciences; Communication; Communities; Data; Development; Discipline; Disease; Education; Ensure; Extramural Activities; Faculty; Feedback; Foundations; Funding; Funding Opportunities; Future; Goals; Health Sciences; Historically Black Colleges and Universities; Human; Human Development; Indiana; Individual; Infrastructure; Institution; International; Knowledge; Leadership; Link; Malignant Neoplasms; Memorial Sloan-Kettering Cancer Center; Mentors; Mentorship; Mission; Monitor; Mutation; NF1 gene; NF1 mutation; National Cancer Institute; Nature; Neurofibromatoses; Pathology; Pediatric Hospitals; Pediatric Oncology; Pediatric Oncology Group; Philadelphia; Pre-Clinical Model; Process; Professional Organizations; Program Development; Request for Applications; Research; Research Personnel; Resources; Role; San Francisco; Schedule; Science; Scientist; Sex Orientation; Signal Transduction; Site; Societies; Structure; Talents; Texas; Textiles; Therapeutic; Therapeutic Trials; Training; Training Programs; Translational Research; Underrepresented Minority; Underrepresented Populations; Universities; Work; anticancer research; base; cancer therapy; career; career development; clinical outcome assessment; clinical translation; design; developmental disease; disability; early-career faculty; effective therapy; efficacy validation; faculty support; hyperactive Ras; innovation; instructor; meetings; member; minority investigator; neoplasm therapy; neuro-oncology; next generation; pharmacokinetics and pharmacodynamics; preclinical study; professor; programs; racial and ethnic; recruit; senior faculty; skills; success; translational scientist; tumor

ABSTRACT– CAREER ENCHANCEMENT PROGRAM The DHART SPORE Career Enhancement Program (CEP) supports faculty at the Instructor and Assistant Professor levels to engage in translational research focused on NF1/Rasopathy disorders and cancer. The primary goal of the CEP is to advance the careers of early stage investigators who are developing innovative research related to the goal of implementing more effective and less toxic therapies for cancers characterized by NF1/Ras. The multi-institutional nature of this SPORE leverages a large and talented pool of early career faculty from multiple disciplines. Each institution views the CEP as a vehicle for recruiting and advancing the careers of early stage translational scientists. Collectively, they have committed $1.3 million to the current award and $1.65 million to the renewal to support the Developmental Programs of the DHART SPORE (CEP and DRP). The Specific Aims of the CEP are to: (1) support early stage investigators as they develop innovative research programs that contribute new knowledge to NF1-related cancer research while generating preliminary data that will allow successful future independent extramural funding; (2) provide early stage researchers with training that will equip them with essential skills and knowledge for success as independent investigators; and, (3) mentor early stage translational researchers through regularly scheduled one-on-one mentor meetings and a structured Individual Development Program (IDP) to facilitate integration into the fabric of the SPORE. The CEP has a special emphasis on supporting the recruitment of underrepresented minority investigators (URM). The DHART SPORE will link vertically and horizontally with diversity programs at all of the consortium institutions and ensure maximum exposure of the CEP mentorship and funding opportunities to URM across the seven DHART SPORE sites. Further, requests for applications (RFA) will be shared with Historically Black Colleges and Universities and professional organizations representing communities under- represented in biomedical science. RFAs are already sent outside of the DHART SPORE sites via the Children’s Tumor Foundation and Neurofibromatosis Therapeutic Acceleration Program. We are expanding this recruitment effort to include the Society for Neuro-Oncology, RASopathies Network USA, the Children’s Oncology Group. The goal is to fund two CEP proposals per year ($50,000 - $75,000/proposal). Requests for applications will be announced twice a year via broad communications to all groups listed above to maximize opportunities for recruitment of diverse scientists and science. CEP opportunities will also be highlighted at professional meetings throughout the year. Applications for CEP support will be evaluated through a competitive process with review by a Developmental Programs Steering Committee comprised of senor scientists from the DHART SPORE with oversight and guidance from the SPORE External and Internal Advisory Boards.

摘要 - 职业增长计划 Dhart Spore职业增强计划（CEP）支持教师和助理的教师 教授级别从事转化研究，重点是NF1/rasopathy疾病和癌症。这 CEP的主要目标是促进正在发展创新的早期研究人员的职业生涯 与实施更有效且毒性更少的癌症的目的有关的研究 由NF1/RAS。该孢子的多机构性质利用了早期职业生涯的大量才华横溢 来自多个学科的教师。每个机构都将CEP视为招募和推进的工具 早期翻译科学家的职业。他们总体上承诺了130万美元 裁定奖励授予续签，以支持Dhart Spore（CEP）的发展计划 和DRP）。 CEP的具体目的是：（1）支持早期调查人员的发展 创新的研究计划，在产生NF1相关的癌症研究的同时为新知识做出贡献 初步数据将允许未来成功的独立壁外资金； （2）提供早期舞台 接受培训的研究人员将使他们具备基本技能和知识，以获得独立的成功 调查人员； （3）精神早期阶段通过定期安排的一对一来翻译研究人员 导师会议和结构化的个人发展计划（IDP），以促进整合到结构中 孢子。 CEP特别强调支持少数派的招募 调查人员（URM）。 Dhart孢子将垂直和水平与多样性计划链接 财团机构并确保最大程度地曝光CEP概念和资金机会 URM跨越了七个Dhart孢子地点。此外，申请请求（RFA）将与 从历史上看，黑人学院，大学以及代表社区不足的社区的专业组织 代表生物医学科学。 RFA已经通过Dhart孢子站点发送 儿童肿瘤基础和神经纤维瘤病治疗加速度计划。我们正在扩展 这项招聘工作是包括神经肿瘤学会，Rasopathies Networe，美国儿童的招聘 肿瘤学小组。目标是每年为两项CEP提案提供资金（50,000美元至75,000美元/提案）。请求 申请将每年两次通过广泛的通信与上述所有小组的广泛沟通，以最大化 招募潜水员科学家和科学的机会。 CEP机会也将在 全年的专业会议。 CEP支持的申请将通过 发育计划指导委员会完成的竞争过程，由Senor完成 Dhart孢子的科学家对孢子外部和内部的监督和指导 咨询委员会。